1. Home
  2. FRSX vs CINGW Comparison

FRSX vs CINGW Comparison

Compare FRSX & CINGW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • FRSX
  • CINGW
  • Stock Information
  • Founded
  • FRSX N/A
  • CINGW N/A
  • Country
  • FRSX Israel
  • CINGW United States
  • Employees
  • FRSX N/A
  • CINGW 13
  • Industry
  • FRSX Computer Software: Prepackaged Software
  • CINGW Biotechnology: Pharmaceutical Preparations
  • Sector
  • FRSX Technology
  • CINGW Health Care
  • Exchange
  • FRSX Nasdaq
  • CINGW Nasdaq
  • Market Cap
  • FRSX N/A
  • CINGW N/A
  • IPO Year
  • FRSX 2017
  • CINGW 2021
  • Fundamental
  • Price
  • FRSX $0.68
  • CINGW $0.06
  • Analyst Decision
  • FRSX
  • CINGW
  • Analyst Count
  • FRSX 0
  • CINGW 0
  • Target Price
  • FRSX N/A
  • CINGW N/A
  • AVG Volume (30 Days)
  • FRSX 38.7K
  • CINGW N/A
  • Earning Date
  • FRSX 11-20-2024
  • CINGW N/A
  • Dividend Yield
  • FRSX N/A
  • CINGW N/A
  • EPS Growth
  • FRSX N/A
  • CINGW N/A
  • EPS
  • FRSX N/A
  • CINGW N/A
  • Revenue
  • FRSX $666,000.00
  • CINGW N/A
  • Revenue This Year
  • FRSX N/A
  • CINGW N/A
  • Revenue Next Year
  • FRSX N/A
  • CINGW N/A
  • P/E Ratio
  • FRSX N/A
  • CINGW N/A
  • Revenue Growth
  • FRSX 86.55
  • CINGW N/A
  • 52 Week Low
  • FRSX $0.63
  • CINGW N/A
  • 52 Week High
  • FRSX $2.10
  • CINGW N/A
  • Technical
  • Relative Strength Index (RSI)
  • FRSX 40.26
  • CINGW N/A
  • Support Level
  • FRSX $0.66
  • CINGW N/A
  • Resistance Level
  • FRSX $0.73
  • CINGW N/A
  • Average True Range (ATR)
  • FRSX 0.03
  • CINGW 0.00
  • MACD
  • FRSX 0.01
  • CINGW 0.00
  • Stochastic Oscillator
  • FRSX 25.41
  • CINGW 0.00

About CINGW Cingulate Inc.

Cingulate Inc is a clinical-stage biopharmaceutical company utilizing its proprietary precision timed-release drug delivery platform to build and advance a pipeline of next-generation pharmaceutical products designed to improve the lives of patients suffering from frequently diagnosed conditions characterized by burdensome daily dosing regimens and suboptimal treatment outcomes. The company focuses on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD) and anxiety, and identifying and evaluating additional therapeutic areas to use PTR technology to develop future product candidates.

Share on Social Networks: